Novo Holdings has invested in the immuno-oncology drug developer which already counts 3SBio Group and Eisai as existing backers.

Lilly Asia Ventures has led a $90m series B round for Duality Biologics, which revealed it has now secured $120m altogether from backers also including WuXi Biologics.

Sparx has returned to lead the OUVC-backed cell-based therapeutic technology developer’s series B round, which brought its overall funding to almost $45m.

Checkout.com-backed Thunes has added $60m to its coffers, while Desktop Metal purchased Adaptive3D less than a year after Arkema invested.

Unnamed corporate investors from the healthcare and life science sectors have helped 7wireVentures close its latest healthcare-focused fund.

Nexa3D has confirmed $55m in funding across several rounds, while BukuKas has added $50m to its coffers and both Label Insights and Mya Systems have been acquired.

Novo, SK Group and Amgen have participated in a series C round for the precision therapy developer that has increased its total funding to at least $150m.

Bos, who featured in last year’s GCV Powerlist, has become a general partner at Forbion after spending 12 years at Merck’s corporate venture capital unit.

Pfizer Ventures and Penn Medicine both contributed to an oversubscribed series A round for University of Pennslyvania spinout Interius Biotherapeutics.

Blue Square Discoveries will involve Deerfield providing funding and business support to researchers at Baylor College of Medicine in the latest such partnership for the investment firm.